Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial

Introduction: Women remain underrepresented in clinical trials and at high risk for CV events in type 2 DM (T2DM). The SGLT-2 inhibitor dapagliflozin (DAPA) reduces CV death or HF hospitalizations ...